Özet:

Multiple sclerosis (MS) and primary headaches are the neurological diseases that most affect the quality of life in young adults. In our study, we aimed to investigate the primary headache frequency, types of MS patients, to shed light on appropriate treatment options, to improve the quality of life of patients and to investigate the relationship between headache and disease modifying drug (DMD)The study included 258 patients with definitive Relapsing Remitting Multiple Sclerosis (RRMS) followed up in the MS outpatient clinic of our hospital. Patients were questioned with the 'Headache Form' prepared in line with the headache diagnostic criteria. Headache rates, sociodemographic characteristics of patients, the relationship of headache with attacks and treatment were examined. The data were analysed with IBM SPSS V18.The mean age of 258 MS patients with 153 (59.3%) headache was 38.03 ± 11.23 years (min-max: 18-66 years), 36.20 ± 13.80 years in women (min- max: 18-64 years), 39.08 ± 14.12 (min-max: 19-66 years) in men. 61.60% of the patients were diagnosed with tension headache (GTBA), 35.94% of migraine, 1.81% of neuralgiform pain and 0.65% of cluster headache. Of the 55 migraine patients, 30.9% were higher than the normal population, with migraine with aura (most often visual-aura). Most of the patients with headache were female (79.7%) and younger (p <0.001). Headache was adversely affected after MS diagnosis in 22.9% of 153 patients; There was an increase in headache frequency in 57.1% and severity in 51.6%. There was no relationship between the duration of the disease and the presence of headache (p> 0.05). With the long-term disease-modifying drugs used, 28.23% worsening was observed in the patients' headache, which was not statistically significant (p> 0.05). Primary headache should be taken into consideration in the planning of diagnosis and tests in MS patients, and unnecessary examinations should be avoided. In conclusion, we expect patients to have better quality of life with appropriate diagnosis and treatment of headache in addition to MS treatment.